Choose a language and wait for the translated text.
Shots:
Avanzanite Bioscience has signed an exclusive license agreement with Cordex Biologics, an ExCellThera company, to commercialize Zemcelpro (dorocubicel + unexpanded CD34- cells) across 32 countries incl. the EEA, UK & Switzerland, incl. potential indication expansion
Avanzanite will become the EU MAH, plans to file MAAs in the UK & Switzerland and will co-fund a planned P-III trial vs haploidentical or mismatched unrelated donor transplant in high-risk acute leukemias & MDS; ExCellThera retains manufacturing, supply & global development
Zemcelpro, an allogeneic UM171-expanded cord blood stem cell therapy, received EC conditional approval (Aug 25, 2025) for adults with hematological malignancies requiring allo-HSCT with no other suitable donor cells
Ref: Business Wire | Image: Avanzanite | ExCellThera | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Avanzanite Bioscience Signs an Exclusive License Agreement with ExCellThera to Commercialize Zemcelpro in Europe appeared first on PharmaShots.
